- CITATIONS: 1
|Application ||WB, E|
|Calculated MW||28671 Da|
|Antigen Region||166-197 aa|
|Other Names||Kallikrein-2, Glandular kallikrein-1, hGK-1, Tissue kallikrein-2, KLK2|
|Target/Specificity||This Kallikrein 2 (KLK2) antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 166-197 amino acids from the C-terminal region of human Kallikrein 2 (KLK2).|
|Format||Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is prepared by Saturated Ammonium Sulfate (SAS) precipitation followed by dialysis against PBS.|
|Storage||Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.|
|Precautions||Kallikrein 2 (KLK2) Antibody (C-term) is for research use only and not for use in diagnostic or therapeutic procedures.|
|Function||Glandular kallikreins cleave Met-Lys and Arg-Ser bonds in kininogen to release Lys-bradykinin.|
Provided below are standard protocols that you may find useful for product applications.
Kallikreins are a group of serine proteases manifesting diverse physiological functions. The glandular kallikreins are a distinct group of serine proteases with an ability to release vasoactive peptides from kininogen in vitro, although the kininogenase activity of different kallikreins is highly variable. Glandular kallikreins cleave Met-Lys and Arg-Ser bonds in kininogen to release Lys-bradykinin. Many kallikrein genes are differentially expressed in various malignancies. Human glandular kallikrein (hK2; encoded by the KLK2 gene) is an emerging tumor marker for prostate cancer.
Haese, A., et al., J Urol. 2005 Mar;173(3):752-6. Chiang, C.H., et al., J Urol. 2005 Feb;173(2):429-32. Clements, J.A., et al., Crit Rev Clin Lab Sci. 2004;41(3):265-312. Borgono, C.A., et al., Mol Cancer Res. 2004 May;2(5):257-80. Yousef, G.M., Clin Biochem. 2003 Sep;36(6):443-52.
If you have any additional inquiries please email technical services at email@example.com.